Calithera Biosciences Inc.

2.05-0.1100-5.09%Vol 824.81K1Y Perf -67.07%
Apr 20th, 2021 16:00 DELAYED
BID2.05 ASK2.06
Open2.14 Previous Close2.16
Pre-Market- After-Market2.07
 - -  0.02 0.98%
Target Price
3.33 
Analyst Rating
Strong Buy 1.00
Potential %
62.44 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap150.30M 
Earnings Rating
Buy
Price Range Ratio 52W %
0.37 
Earnings Date
6th May 2021

Today's Price Range

2.032.15

52W Range

2.037.42

5 Year PE Ratio Range

-4.20-4.20

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-6.39%
1 Month
-25.18%
3 Months
-30.03%
6 Months
-42.58%
1 Year
-67.07%
3 Years
-66.39%
5 Years
-65.25%
10 Years
-

TickerPriceChg.Chg.%
CALA2.05-0.1100-5.09
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.32-0.320.00
Q03 2020-0.31-0.32-3.23
Q02 2020-0.33-0.2912.12
Q01 2020-0.37-0.38-2.70
Q04 2019-0.39-0.390.00
Q03 2019-0.49-0.3822.45
Q02 2019-0.55-0.58-5.45
Q01 2019-0.43-0.61-41.86
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.273.57Positive
6/2021 QR-0.234.17Positive
12/2021 FY-0.852.30Positive
12/2022 FY-0.7112.35Positive
Next Report Date6th May 2021
Estimated EPS Next Report-0.27
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume824.81K
Shares Outstanding73.32M
Trades Count3.80K
Dollar Volume3.07M
Avg. Volume1.57M
Avg. Weekly Volume578.32K
Avg. Monthly Volume814.46K
Avg. Quarterly Volume1.11M

Calithera Biosciences Inc. (NASDAQ: CALA) stock closed at 2.05 per share at the end of the most recent trading day (a -5.09% change compared to the prior day closing price) with a volume of 825.95K shares and market capitalization of 150.30M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 93 people. Calithera Biosciences Inc. CEO is Susan M. Molineaux.

The one-year performance of Calithera Biosciences Inc. stock is -67.07%, while year-to-date (YTD) performance is -58.25%. CALA stock has a five-year performance of -65.25%. Its 52-week range is between 2.03 and 7.42, which gives CALA stock a 52-week price range ratio of 0.37%

Calithera Biosciences Inc. currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 1.54, a price-to-sale (PS) ratio of -, a price to cashflow ratio of 14.70, a PEG ratio of 2.32, a ROA of -58.28%, a ROC of -70.41% and a ROE of -70.03%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Calithera Biosciences Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.27 for the next earnings report. Calithera Biosciences Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Calithera Biosciences Inc. is Strong Buy (1), with a target price of $3.33, which is +62.44% compared to the current price. The earnings rating for Calithera Biosciences Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Calithera Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Calithera Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.47, ATR14 : 0.18, CCI20 : -130.73, Chaikin Money Flow : -0.19, MACD : -0.27, Money Flow Index : 27.95, ROC : -10.74, RSI : 32.62, STOCH (14,3) : 17.02, STOCH RSI : 0.17, UO : 42.60, Williams %R : -82.98), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Calithera Biosciences Inc. in the last 12-months were: Keith Orford (Sold 2 447 shares of value $14 682 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Calithera Biosciences Inc.

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm is functioned through the region of US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

CEO: Susan M. Molineaux

Telephone: +1 650 870-1000

Address: 343 Oyster Point Boulevard, South San Francisco 94080, CA, US

Number of employees: 93

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

44%56%

Bearish Bullish

57%43%

Bearish Bullish

52%48%

News

Stocktwits